Core Insights - Pluri Inc. has received a patent from the U.S. Patent and Trademark Office for its immune cell expansion technologies, specifically for MAIT cells, which are important for fighting infections and tissue repair [1][4] - The company has also secured a corresponding patent in Israel, bringing its total intellectual property estate to over 250 patents [1] - Pluri's MAIT cells, derived from the placenta, are positioned as a promising solution for treating solid tumors, addressing a significant unmet medical need in immunotherapy [2][5] Intellectual Property and Technology - The newly granted patents focus on large-scale culturing and activation of immune cells using Pluri's proprietary 3D cell expansion bioreactors [3][7] - Pluri's 3D cell expansion technology mimics the natural environment of lymph nodes, allowing for efficient and high-quality immune cell expansion [8] Market Potential - The global immune cell engineering market is projected to reach approximately $11.7 billion by 2030, while the global cancer immunotherapy market is estimated at $136 billion in 2025 [7] - Pluri's MAIT platform not only supports the expansion of MAIT cells but also Tumor Infiltrating Lymphocytes (TILs), broadening the scope of potential therapies in cancer immunotherapy [7] Strategic Vision - The CEO of Pluri emphasizes the potential of MAIT cells in immunotherapy and the company's capability to scale production, positioning it for collaborations that could deliver immune therapies to patients [4] - Pluri aims to develop its proprietary placental-derived MAIT cell immunotherapy platform to revolutionize solid tumor treatment and support other companies in commercializing their immunotherapy treatments [4][6]